Marker Therapeutics closed at $1.01 on Nov 4, up 2.76%, 53.9% below its 52-week closing high. Volume of 94.4K shares was 0.48× its 20-day average (below normal).
Split-adjusted performance: +0.0% over one month, -30.8% over six months, +5.3% over one year.
Short interest was 109.1K shares at the Oct 15 settlement, down 35.4% from the prior report (0.8% of float, 1.1 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MRKRMarker Therapeutics | $1.01 | +2.76% | −30.8% | — | — | — | $16.8M | |
| MTEXMannatech | $8.64 | −0.06% | +77.0% | +3.8% | 3.8% | — | $16.7M | Compare |
| ALLRAllarity Therapeutics | $1.08 | −4.42% | −27.0% | — | — | — | $17.2M | Compare |
| NEUPNeuphoria Therapeutics | $2.98 | −0.33% | −44.6% | — | — | — | $16.1M | Compare |
| KYNBKyntra Bio | $3.96 | −8.12% | −44.4% | — | — | — | $16.0M | Compare |
| KTTAPasithea Therapeutics | $0.5300 | 0.00% | −37.6% | — | — | — | $17.7M | Compare |
| BOLTBolt Biotherapeutics | $6.54 | −0.46% | +42.5% | −99.7% | −154400.0% | — | $15.4M | Compare |
| CNTXContext Therapeutics | $0.2035 | +4.90% | −91.6% | — | — | — | $18.7M | Compare |
| CTXRCitius Pharmaceuticals | $0.5510 | −3.87% | −17.3% | — | −593.3% | — | $15.1M | Compare |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
